Cardiac Surgery Company CyroLife Signs Option to Acquire Israel-Based EndoSpan for up to $450 Million

An illustration of the human heart. Photo: Patrick J. Lynch via Wikicommons.

CTech – NYSE-listed cardiac and vascular surgery company CyroLife has signed a distribution agreement, credit facilities, and option agreement to acquire Israel-based stent graft company EndoSpan, the two announced Wednesday.

Founded in 2008 and based in Israeli central town Herzliya, EndoSpan develops stent graft systems for treating aneurysms and dissections throughout the aorta. Its Horizon system for endovascular treatment of abdominal aortic aneurysms is currently in preparations for starting an approval process in Europe. Its Nexus system for treating aortic arch disease has already received a CE Mark (European approval).

Under the deal, CyroLife will pay EndoSpan $10 million for the European distribution rights for Nexus, and provide up to $15 million in debt financing subject to Endospan’s progress in its US clinical trial as its works towards US Food and Drug Administration (FDA) approval. The option agreement gives CyroLife 90 days from the FDA approval to acquire EndoSpan for $350 million plus up to an additional $100 million depending on the commercial success of the system.

Visit the USSA News store!
Click this link for the original source of this article.
Author: Meir Orbach / CTech

This content is courtesy of, and owned and copyrighted by, and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact the administrator by using the contact form located in the top-left menu. Your request will be immediately honored. Please visit for more terrific, conservative content. The owner of this website may be paid to recommend American Bullion. The content of this website, including the positive review of American Bullion, the negative review of its competitors, and any other information may not be independent or neutral.